A5058722338- Acute Myeloid Leukemia Research
- Colorectal Cancer Treatments and Studies
- Erythrocyte Function and Pathophysiology
- Gastric Cancer Management and Outcomes
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Surgical Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Colorectal and Anal Carcinomas
- Cancer Treatment and Pharmacology
- Hepatocellular Carcinoma Treatment and Prognosis
- Genetic factors in colorectal cancer
- Cutaneous Melanoma Detection and Management
- Optical Coherence Tomography Applications
- Esophageal Cancer Research and Treatment
- Asthma and respiratory diseases
- Vascular Tumors and Angiosarcomas
- Cardiac tumors and thrombi
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Liver physiology and pathology
- Eosinophilic Disorders and Syndromes
BC Cancer Agency
2023-2025
Flinders Medical Centre
2025
University of British Columbia
2024-2025
Calvary Hospital
2021-2023
Queen Elizabeth Hospital
2020-2021
Royal Adelaide Hospital
2020
GTx (United States)
2020
The University of Adelaide
2020
<p>Prevalence of CHIP variants across cohorts and association with age. <b>A,</b> Percentage patients in each cohort. Insert shows the breakdown by tumor type PREDiCT-l <b>B,</b> Number a variant gene; <i>DNMT3A</i>, <i>TET2</i>, <i>ASXL1</i>. <b>C,</b> Protein position coding gene. Each lollipop represents patient, multiple dots show same position, red outlines high impact (frameshift or stop gain). Orange bars...
<p>Consort diagram and reasons for exclusion.</p>
<p>CHIP and adverse events. <b>A,</b> Percentage of patients on each treatment that had an event therapy, split by cohort treatment. <b>B,</b> Proportions with events CHIP status. Lighter shades indicate no event, darker event. <i>P</i> values were determined Fisher exact tests.</p>
<p>Progression free survival for patients on PREDiCT-l, split by tumor type. Therapy received is indicated in each title above Kaplan Meier curve.</p>
<p>TRIPOD checklist</p>
<p>CHIP and treatment outcomes. Kaplan–Meier curves showing the difference in outcome between patients with (CHIP+) without CHIP (CHIP−) outcomes on different therapies. PFS is shown left two columns for all three cohorts, OS right CO.26 (top row) PA.7 (middle row). Hazard ratios displayed are derived from univariable Cox proportional hazards models, interaction <i>P</i> values multivariable models (see “Materials Methods”).</p>
<p>VAF of all CHIP variants split by cohort</p>
<div>Abstract<p>Clonal hematopoiesis of indeterminate potential (CHIP) is the clonal expansion hematopoietic stem cells from somatic mutations. It a common incidental finding in cell-free DNA (cfDNA). We investigated incidence CHIP cfDNA patients with solid tumors and explored its association treatment outcomes adverse events. reviewed results local prospective tumor cohort (PREDiCT-l) two randomized trials: Canadian Cancer Trials Group CO.26 [durvalumab + tremelimumab (D T) or...
<p>All CHIP variants identified in the study</p>
<p>Baseline characteristics of the included patients</p>
275 Background: While detection of MRD using ctDNA is prognostic for recurrence in CRC, some patients still recur prior to detection. VICTORI prospectively investigating NeXT Personal, an ultra-sensitive NGS-based assay, profile with resected CRC. Methods: Patients CRC treated curative intent (all stages) are tested a bespoke assay up ~1,800 tumor-informed single nucleotide variants (SNVs) identified from whole-genome sequencing. Plasma collected surgery, every 2 weeks post-surgery week 8...
253 Background: The treatment landscape for metastatic colorectal cancer (mCRC) has evolved significantly, shifting from chemotherapy alone to more personalized approaches that include immune checkpoint inhibitors and targeted therapies. Treatment decisions in mCRC are driven by molecular characteristics, current guidelines recommend a minimum standard of biomarker testing, such as mismatch repair (MMR) status, RAS BRAF mutations, at the time disease diagnosis guide selection. This study...
Advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) constitute a heterogeneous group of incurable cancers. Lenvatinib is an oral multiple kinase inhibitor that showed activity in grade 1/2 GEP-NENs the phase II TALENT trial, but confirmatory III study has yet to be conducted. To investigate real-world use lenvatinib treating patients with advanced GEP-NENs, we retrospectively analyzed cohort adults unresectable (NENs) from two academic centers Canada who received palliative...
To investigate eosinophilia as a potential on-treatment biomarker for patients receiving cancer immunotherapy.We evaluated the association between and treatment response toxicity in retrospective cohort of immunotherapy.The study involved 146 patients. Eosinophilia developed 22%. Patients who were more likely to achieve disease control (p = 0.009), with every 0.1 × 109/l rise eosinophil count, while was associated 28% relative increased chance achieving control. Although there trend toward...
4098 Background: Advances in systemic therapy for HCC have increased treatment options, including TKIs and immunotherapy combinations. Variables that predict patient outcomes may be helpful personalizing decisions. The aim of this study was to identify predictors short-term death (STD) long-term survival (LTS) patients. Methods: Retrospective review patients with advanced who received a TKI or combinations conducted between Aug 2018 2022 the Canadian provinces British Columbia, Alberta, Nova...
169 Background: Clonal hematopoesis of indeterminate potential (CHIP) is the acquisition somatic mutations leading to clonal expansion hematopoietic stem cells and a common incidental finding in circulating tumor DNA (ctDNA). Inflammation from these or reduced marrow reserve may impact treatment outcomes adverse events. We investigated incidence CHIP ctDNA patients with gastrointestinal (GI) cancers explored its association events (AEs). Methods: collected results local prospective...
4111 Background: Lenvatinib (LEN) and the combination of atezolizumab with bevacizumab (AB) are widely considered first-line systemic therapies for treatment advanced hepatocellular carcinoma (HCC), but have never been compared directly in a randomized clinical trial. Cross-trial comparisons between IMbrave150 LEAP-002 appear to show similar survival outcomes AB LEN, respectively, while LEN was shorter REFLECT Methods: Patients treated or HCC from August 2018 2022 Canadian provinces British...
Introduction: A comprehensive trimodality approach has become the standard of care for patients with locally advanced rectal cancer. However, sequencing and duration chemotherapy chemoradiotherapy around surgery varies between clinical studies geographical regions. Growing evidence is also mounting strategies such as total neoadjuvant therapy non-operative management carefully selected patients.Areas covered: We provide a perspective review current controversies in treatment cancer including...
Abstract Octreotide LAR is a long‐acting somatostatin analogue (SSA) used in the management of metastatic gastroenteropancreatic neuroendocrine tumors (GEP NETs). It requires intramuscular (IM) injection. Missed IM injections cause subcutaneous nodules (SCNs) on radiologic images. We reviewed rates SCNs real‐world cohort GEP NETs receiving octreotide and explored treatment outcomes. Patients commencing between August 5, 2010 March 8, 2018 at single cancer center Canada were identified from...
83 Background: Based on the IDEA analysis, 3 months (mos) of adjuvant chemotherapy (ACT) with CAPOX has emerged as an option for both low-risk and high-risk stage III CRC. This resource utilization, cost toxicity benefits (particularly less neurotoxicity) without compromising efficacy. study examines patterns uptake vs FOLFOX duration ACT in a contemporary post-COVID real-world cohort patients (pts) province British Columbia (BC), Canada. Methods: The provincial pharmacy database was used to...
Background: Complete resection followed by adjuvant chemotherapy is the gold standard for patients with localized cholangiocarcinoma (CC) or gallbladder cancer (GBC). However, this not always feasible, and recurrence rates remain high. Objectives: To understand real-world proportions reason treatment failure in resected biliary tract cancers. Design methods: We performed a retrospective population-based review of GBC CC [intrahepatic (IHCC) extrahepatic (EHCC)] between 2005 2019 using BC...